Targeted messaging for Obesity

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Massachusetts General Hospital, Boston, MA
Obesity+9 More
Targeted messaging - Behavioral
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

Chronic health conditions affect most older adults. Preventative medicine and risk management strategies, especially when applied earlier in life, are essential to altering the trajectory of a disease and ultimately improving health outcomes. Primary care providers (PCP) often provide most of these services, though younger adults are the least likely to receive primary care. This project leverages a period of high engagement and health activation during an individual's life (pregnancy) to nudge her toward use of primary care after the pregnancy episode. This randomized controlled trial will test the hypothesis that a behavioral science-informed intervention, incorporating defaults and salience, can increase the rates of PCP follow-up within 4 months following a delivery for individual with hypertension, diabetes, obesity. If successful, this intervention could serve as a scalable solution to increase primary care use and preventative health services in a population that currently has low rates of engagement and utilization of these services.

Eligible Conditions

  • Obesity
  • Hypertension in Pregnancy
  • Gestational Diabetes Mellitus (GDM)
  • Anxiety Disorders
  • Hypertension
  • Melancholia
  • Diabetes Mellitus

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obesity

Study Objectives

0 Primary · 17 Secondary · Reporting Duration: 4 months after the patient's estimated date of delivery

Month 12
Rate of antidepressant use among individuals with mood or anxiety disorders
Rate of antihypertensive use among individuals with hypertension
Rate of assessment of glycemic control among individuals with or at risk for diabetes
Rate of blood pressure measurement documented in the health record among those with or at risk for hypertension
Rate of contraception plan documented
Rate of long-acting contraception use
Rate of medication use for glycemic control among individuals with diabetes
Rate of mental health service referral or use among individuals with mood or anxiety disorders
Rate of patient-reported primary care visit attendance
Rate of pregestational diabetes screening among individuals with gestational diabetes
Rate of primary care provider visit attendance
Rate of visit unscheduled health care visit/encounter
Rate of visit with a patient's assigned primary care provider for receipt of "annual" or "health care maintenance" services OR disease-specific management (diabetes, hypertension, obesity, mental health)
Rate of weight counseling documented in the health record among those with obesity
Month 4
Rate of contraception plan documented by the time of outcome assessment
Rate of long-acting contraception use at time of outcome assessment
Rate of visit unscheduled health care visit/encounter by the time of outcome assessment

Trial Safety

Safety Progress

1 of 3

Other trials for Obesity

Trial Design

2 Treatment Groups

Control
1 of 2
Facilitated Transition
1 of 2
Active Control
Experimental Treatment

350 Total Participants · 2 Treatment Groups

Primary Treatment: Targeted messaging · No Placebo Group · N/A

Facilitated TransitionExperimental Group · 3 Interventions: Nudge Reminders, Targeted messaging, Default appointment scheduling · Intervention Types: Behavioral, Behavioral, Behavioral
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Targeted messaging
2012
N/A
~450

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 months after the patient's estimated date of delivery
Closest Location: Massachusetts General Hospital · Boston, MA
Photo of Massachusetts General Hospital 1Photo of Massachusetts General Hospital 2Photo of Massachusetts General Hospital 3
1993First Recorded Clinical Trial
40 TrialsResearching Obesity
2430 CompletedClinical Trials

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,660 Previous Clinical Trials
30,828,447 Total Patients Enrolled
65 Trials studying Obesity
145,948 Patients Enrolled for Obesity
National Bureau of Economic Research, Inc.OTHER
26 Previous Clinical Trials
585,384 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,348 Previous Clinical Trials
3,261,547 Total Patients Enrolled
38 Trials studying Obesity
11,863 Patients Enrolled for Obesity
Massachusetts Institute of TechnologyOTHER
81 Previous Clinical Trials
18,162,695 Total Patients Enrolled
3 Trials studying Obesity
3,439 Patients Enrolled for Obesity
Jessica L Cohen, PhDPrincipal InvestigatorHarvard School of Public Health (HSPH)
1 Previous Clinical Trials
10,992 Total Patients Enrolled
Mark A Clapp, MD, MPHPrincipal InvestigatorMassachusetts General Hospital

Eligibility Criteria

Age 18+ · Female Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a primary care provider listed in the EHR.
The study is completed within 4 months of delivery.
You have one or more of the following conditions: 1) Chronic hypertension, 2) Hypertensive disorders of pregnancy or risk factors for hypertensive disorders of pregnancy per the USPSTF aspirin prescribing guidelines (e.g.
You are pregnant and are expected to deliver at the study institution's outpatient prenatal clinic.
You are able to read and/or speak English or Spanish language.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.